The Tomazou lab, at the St. Anna Children's Cancer Research Institute in the medical hub of Vienna, aims to establish an epigenome-based precision medicine program for pediatric sarcomas.

The goal of our research group is to uncover the roles of epigenetic deregulation as an oncogenic mechanism, with a focus on fusion-driven pediatric sarcomas. We study how fusion proteins rewire healthy cells for malignancy, with the perspective of exploiting this knowledge for improving pediatric sarcoma therapy. We are applying state-of-the-art technologies that combine wet-lab and computational methods investigating:

​

• Non-genetic mechanisms of tumor formation orchestrated by oncogenic fusion proteins

• Contribution of the cellular state of the corresponding cell of origin to cancer development

• Epigenetic heterogeneity as source of cellular plasticity providing novel therapeutic paradigms

• Non-genetic based biomarkers for patient stratification and real time disease monitoring